Publications by authors named "Manoj Chevli"

Claim this Profile
O
Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemia.
Alice Mims, Zhuoer Xie, Ravi Potluri, David Rotter, Manoj Chevli

Leuk Lymphoma· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world treatment patterns and health outcomes for patients with myelofibrosis treated with fedratinib.
Francesco Passamonti, Siddhi Korgaonkar, Rohan C Parikh, Manoj Chevli, Aylin Yucel

Future Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare Utilization and Costs Among Patients with Acute Myeloid Leukemia Receiving Oral Azacitidine Maintenance Therapy Versus No Maintenance: A US Claims Database Study.
Uma Borate, Karen Seiter, Ravi Potluri, Debasish Mazumder, Manoj Chevli

Adv Ther· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes with fedratinib therapy in patients who discontinued ruxolitinib for primary myelofibrosis.
Francesco Passamonti, Youbei Lou, Manoj Chevli, Pranav Abraham

Future Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health state utilities for beta-thalassemia: a time trade-off study.
Antony P Martin, Enrico Ferri Grazzi, Claudia Mighiu, Manoj Chevli, Farrukh Shah

Eur J Health Econ· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personal and societal costs of multiple sclerosis in the UK: A population-based MS Registry study.
Richard S Nicholas, Martin L Heaven, Rodden M Middleton, Manoj Chevli, Ruth Pulikottil-Jacob

Mult Scler J Exp Transl Clin· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis